In vitro antibacterial activity and mechanism of artesunate on Propionibacterium acnes

doi:10.3969/j.issn.1673-8640.2020.04.007

Abstract

Abstract:

Objective To investigate the in vitro antibacterial activity and mechanism of artesunate on Propionibacterium acnes. Methodse The minimum inhibitory concentrations（MIC） of artesunate combined with doxycycline hydrochloride to 14 standard and clinical isolates of Propionibacterium acnes were determined by broth microdilution method. Dynamic effects of the 2 drugs on the growth of Propionibacterium acnes were observed. Morphological changes of Propionibacterium acnes after artesunate treatment were observed by scanning electron microscopy. Results The MIC of artesunate was 0.750-3.000 mg/mL,and the MIC of doxycycline hydrochloride was 0.040-0.160 μg/mL. The 2 drugs showed additive or synergistic effect. The MIC difference between single drug and combined drugs was statistically significant（P<0.05）. Bacterial growth kinetics indicated that the combined drugs decreased the concentration of each drug,and the antibacterial action was rapid and long-lasting. Scanning electron microscopy showed that the bacteria became short after the action of artesunate,and the surface was wrinkled,sunk and curved. Conclusions Artesunate has antibacterial activity against Propionibacterium acnes. The combined action of artesunate and doxycycline hydrochloride is superior to single action. Artesunate has a morphological effect on Propionibacterium acnes.

Key words: Propionibacterium acnes, Artesunate, Doxycycline hydrochloride, Antibacterial activity

CLC Number:

R378.99

CHEN Xiangming, HE Ping, LI Tin, ZHANG Haiqing, HU Yang. In vitro antibacterial activity and mechanism of artesunate on Propionibacterium acnes[J]. Laboratory Medicine, 2020, 35(4): 318-322.

Figures/Tables 4

References 15.

1.	KIRCIK L H.Re-evaluating treatment targets in acne vulgaris:adapting to a new understanding of pathophysiology[J]. J Drugs Dermatol,2014,13(6):s57-s60.
2.	HOLLAND C,MAK T N,ZIMNY-ARNDT U,et al.Proteomic identification of secreted proteins of Propionibacterium acnes[J]. BMC Microbiol,2010,10:230.
3.	李婷,胡阳,俞爱华,等. 口服青蒿琥酯治疗酒渣鼻31例临床观察[J]. 中国皮肤性病学杂志,2015,29(3):330-332.
4.	YAMASAKI K,KANADA K,MACLEOD D T,et al.TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes[J]. J Invest Dermatol,2011,131(3):688-697.
5.	ADJUIK M,BABIKER A,GARNER P,et al.Artesunate combinations for treatment of malaria:meta-analysis[J]. Lancet,2004,363(9402):9-17.
6.	李斌,周红. 青蒿素及其衍生物药理作用研究有关进展[J]. 中国临床药理学与治疗学,2010,15(5):572-576.
7.	吕品,秦玉花,王山梅,等. 青蒿琥酯对耐甲氧西林金黄色葡萄球菌体外抗菌活性研究[J]. 中华实用诊断与治疗杂志,2015,29(7):643-644.
8.	蒋为薇. 青蒿琥酯增强β-内酰胺类抗生素对耐甲氧西林金黄色葡萄球菌(MRSA)脓毒症模型小鼠的保护作用及机制研究[D]. 重庆:第三军医大学,2011.
9.	SILVA C S,FIGUEIREDO H M,STAMFORD T L M,et al. Inhibition of listeria monocytogenes by Melaleuca alternifolia(tea tree) essential oil in ground beef[J]. Int J Food Microbiol,2019,293:79-86.
10.	CAPOOR M N,BIRKENMAIER C,WANG J C,et al.A review of microscopy-based evidence for the association of Propionibacterium acnes biofilms in degenerative disc disease and other diseased human tissue[J]. Eur Spine J,2019,28(12):2951-2971.
11.	DEL POZO J L. Biofilm-related disease[J]. Expert Rev Anti Infect Ther,2018,16(1):51-65.
12.	COENYE T,PEETERS E,NELIS H J.Biofilm formation by Propionibacterium acnes is associated with increased resistance to antimicrobial agents and increased production of putative virulence factors[J]. Res Microbiol,2007,158(4):386-392.
13.	郭锦锦,芦起,冯蕾,等. 青蒿琥酯对铜绿假单胞菌生物膜形成及结构的影响[J]. 基因组学与应用生物学,2018,37(8):3733-3739.
14.	ZENG Q P,XIAO N,WU P,et al.Artesunate potentiates antibiotics by inactivating heme-harbouring bacterial nitric oxide synthase and catalase[J]. BMC Res Notes,2011,4:223.
15.	LIN Y,TANG G,JIAO Y,et al.Propionibacterium acnes induces intervertebral disc degeneration by promoting iNOS/NO and COX-2/PGE2 activation via the ROS-dependent NF-κB pathway[J]. Oxid Med Cell Longev,2018,2018:3692752.

菌株	单独用药		联合用药
菌株	青蒿琥酯/（mg/mL）	盐酸多西环素/（µg/mL）	青蒿琥酯/（mg/mL）	盐酸多西环素/（µg/mL）	FIC
标准株	0.750	0.040	0.188	0.010	0.501
临床株 1	0.750	0.080	0.094	0.040	0.625
临床株 2	1.500	0.040	0.375	0.020	0.750
临床株 3	0.750	0.040	0.375	0.005	0.625
临床株 4	0.750	0.080	0.375	0.020	0.750
临床株 5	0.375	0.080	0.188	0.020	0.751
临床株 6	1.500	0.160	0.750	0.040	0.750
临床株 7	1.500	0.040	0.375	0.010	0.500
临床株 8	0.750	0.080	0.188	0.020	0.501
临床株 9	0.750	0.040	0.094	0.010	0.375
临床株 10	3.000	0.160	0.375	0.040	0.375
临床株 11	0.750	0.080	0.375	0.040	1.000
临床株 12	1.500	0.040	0.750	0.005	0.625
临床株 13	0.375	0.080	0.188	0.010	0.626

菌株	单独用药		联合用药
菌株	青蒿琥酯/（mg/mL）	盐酸多西环素/（µg/mL）	青蒿琥酯/（mg/mL）	盐酸多西环素/（µg/mL）	FIC
标准株	0.750	0.040	0.188	0.010	0.501
临床株 1	0.750	0.080	0.094	0.040	0.625
临床株 2	1.500	0.040	0.375	0.020	0.750
临床株 3	0.750	0.040	0.375	0.005	0.625
临床株 4	0.750	0.080	0.375	0.020	0.750
临床株 5	0.375	0.080	0.188	0.020	0.751
临床株 6	1.500	0.160	0.750	0.040	0.750
临床株 7	1.500	0.040	0.375	0.010	0.500
临床株 8	0.750	0.080	0.188	0.020	0.501
临床株 9	0.750	0.040	0.094	0.010	0.375
临床株 10	3.000	0.160	0.375	0.040	0.375
临床株 11	0.750	0.080	0.375	0.040	1.000
临床株 12	1.500	0.040	0.750	0.005	0.625
临床株 13	0.375	0.080	0.188	0.010	0.626